After a relatively slow deal making year in 2022, there have been early signs that an uptick in business development activity could be seen in 2023. The appetite for M&A seemingly bounced back within the first two weeks of the year when a flurry of bolt-on acquisitions were announced, as companies looked to add promising assets to their priority therapeutic areas. Notable deals include Chiesi’s acquisition of Amryt Pharma, Ipsen’s purchase of Albireo and AstraZeneca’s takeover of CinCor Pharma.